Perceptive Discovery offers a comprehensive portfolio of radioligand binding assays to support drug development with precision and reliability.
Our global platform integrates radiochemistry services, in vitro and ex vivo pharmacology, homogenate binding and autoradiography techniques to support compound characterization. Our specialized services deliver actionable insights to ensure translational relevance for drug development programs, including those focused on radioligand therapy and theranostics.
Your trusted partner in pharmacology
Our services include saturation binding assays for detailed analysis of target expression and ligand affinity, competition assays to evaluate candidate specificity, and cell-based target internalization studies to explore receptor-mediated endocytosis.
With expertise in kinetic analyses and specialized techniques such as Immunoreactive Fraction Assays (IRF) and ex vivo dose occupancy assays, we deliver actionable insights to drive informed decisions and ensure translational relevance. Learn more:
In order to de-risk the development of a novel radioligand or to understand the powering of a study associated with altered target expression in disease state, we can perform in vitro autoradiography or homogenate saturation binding assays to measure the target expression (maximum binding signal, BMAX) and ligand affinity (dissociation constant, KD) by traditional pharmacology methods in ethically sourced animal and human tissue.
Perspective offers competition binding assays performed to determine the relative affinity (Ki) of unlabelled candidates and to determine whether they share the same binding site as a radiolabelled tool compound.
Cell-based target internalisation assays can be performed to investigate aspects of receptor-mediated endocytosis and the time course associated with this phenomenon.
Kinetic parameters such as the association (Kon) and dissociation (koff) may be determined by using a radiolabelled candidate to establish ligand kinetics.
Other radioligand binding assay approaches used for specific applications include Immunoreactive Fraction Assays (IRF) and ex vivo dose occupancy assays.
Perceptive Discovery is more than just a service provider – we are your trusted imaging partner, supporting drug development from preclinical imaging through translational research and into late-phase clinical trials. Our integrated services are designed to meet your needs at every step. Let’s discuss your next project:
Reach out today and one of our solution experts will be in touch to learn about your specific needs.
